Infant Bacterial (Sweden) Insiders
| IBT-B Stock | SEK 49.30 1.30 2.57% |
Infant Bacterial employs about 5 people. The company is managed by 5 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Infant Bacterial's management performance can provide insight into the firm performance.
| Anders Kronstrm Insider Chief Officer |
| Maria Ekdahl Insider Chief Officer |
Infant |
Infant Bacterial Management Team Effectiveness
The company has return on total asset (ROA) of (0.1085) % which means that it has lost $0.1085 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1801) %, meaning that it generated substantial loss on money invested by shareholders. Infant Bacterial's management efficiency ratios could be used to measure how well Infant Bacterial manages its routine affairs as well as how well it operates its assets and liabilities.Infant Bacterial Workforce Comparison
Infant Bacterial Therapeutics is rated fourth overall in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 334. Infant Bacterial claims roughly 5.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Infant Bacterial Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Infant Bacterial Price Series Summation is a cross summation of Infant Bacterial price series and its benchmark/peer.
Infant Bacterial Notable Stakeholders
An Infant Bacterial stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Infant Bacterial often face trade-offs trying to please all of them. Infant Bacterial's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Infant Bacterial's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anders Kronstrm | Chief Officer | Profile | |
| Maria Ekdahl | Chief Officer | Profile | |
| Robert Molander | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Staffan Stromberg | Chief Officer | Profile |
About Infant Bacterial Management Performance
The success or failure of an entity such as Infant Bacterial often depends on how effective the management is. Infant Bacterial management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Infant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Infant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Infant Bacterial's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Infant Bacterial Therapeutics. Check Infant Bacterial's Beneish M Score to see the likelihood of Infant Bacterial's management manipulating its earnings.
Infant Bacterial Workforce Analysis
Traditionally, organizations such as Infant Bacterial use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Infant Bacterial within its industry.Infant Bacterial Manpower Efficiency
Return on Infant Bacterial Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 9M | |
| Net Loss Per Executive | 9M |
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.